Market Cap 3.36B
Revenue (ttm) 434.43M
Net Income (ttm) 275.19M
EPS (ttm) N/A
PE Ratio 73.32
Forward PE N/A
Profit Margin 63.35%
Debt to Equity Ratio 0.00
Volume 275,052
Avg Vol 863,434
Day's Range N/A - N/A
Shares Out 61.98M
Stochastic %K 35%
Beta 2.26
Analysts Strong Sell
Price Target $68.45

Company Profile

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 474 0170
Address:
7707 Gateway Boulevard, Suite 140, Newark, United States
Quantumup
Quantumup Jul. 23 at 6:25 PM
H.C. Wainwright reit'd $ORKA Buy/$45 after Oruka📰that the FDA had cleared its IND application for its Phase 2a trial of ORKA-001 (the company's long-acting anti-IL-23p19 antibody) in moderate-to-severe PsO, called EVERLAST-A. $ABBV $PTGX - $JNJ #EDAV25 H.C. Wainwright said in its note: "This program is a randomized, double-blind, placebo-controlled Phase 2a trial designed to evaluate the safety and efficacy of a single dose level of ORKA-001 in moderate-to-severe psoriasis patients. EVERLAST-A will enroll approximately 80 patients, randomized 3:1 to receive ORKA-001 or matching placebo. The primary endpoint is PASI 100 at Week 16. ORKA-001 exposures are expected to match or exceed exposures in the KNOCKOUT study, providing a definitive test of whether higher exposures of an anti-IL-23p19 antibody can lead to greater efficacy. H.C. Wainwright went on to say:
0 · Reply
Quantumup
Quantumup Jul. 23 at 12:07 PM
Citizens⬆️ $ABVX to $95, reit Mkt-OP &said, "Stellar Phase 3 results for obefazimod in ulcerative colitis support potential for broad and early use in clinical practice" $ABBV $BMY PFE TAK $JNJ $PTGX VYTX LLY Guggenheim⬆️ $ABVX $101, reit Buy &said data clearly beat its/Buyside's exps.—believes obe S/B valued $7-10B range, given the recent M&A comps—Gugg's KOL called data "striking" Citizens said, "we reiterate our Market Outperform rating and increase our risk-adjusted, DCF-derived price target to $95 from $33 on Abivax SA. Yesterday afternoon, Abivax announced positive results from the two Phase 3 induction trials for obefazimod in moderate-to-severe ulcerative colitis. We view the results as highly compelling, with a pooled, placebo-adjusted clinical remission rate of 16.4% (p<0.0001) and a clean safety/tolerability profile. We raise our probability of approval and sales projections for the candidate, driving our increased price target." Guggenheim in its note said:
0 · Reply
Quantumup
Quantumup Jul. 21 at 1:15 PM
Stifel reiterated $ORKA Buy-$47 after $ORKA's disclosure of the IND clearance for ORKA-001 and then catching up w/ mgmt.. $ABBV $PTGX $JNJ #EADV25 UCBJY $MLTX Stifel said in its note: "We caught up with management who noted that the IND clearance was based on interim Ph1 data (safety/tolerability) and Ph2a sites are open and actively enrolling -- Ph1 results to be presented at #EADV in September. Recall, ORKA-001 is a next-gen IL-23p19 which is designed to explore greater exposure and improved dosing vs. mega-blockbuster Skyrizi based on exploratory IST results in Psoriasis demonstrating superior efficacy/potential for remission in patients dosed with 4x the normal psoriasis dose (LINK). Meanwhile, $ORKA is on track to release Ph1 data for ORKA-002 (next-gen IL-17A/F mAb) by YE25 following a continued strong launch for Bimzelx and upcoming Ph3 data for $MLTX's sonelokimab -- there is currently limited investor focus on $ORKA as a player in the IL-17A/F space."
0 · Reply
Quantumup
Quantumup Jul. 18 at 11:07 AM
Citizens reiterated $ABVX at a Market Outperform rating, a $33 PT and a High-Conviction name after its confidence in the pot'l for +VE obefazimod Ph3 results in moderate-to-severe ulcerative colitis were reinforced by its #KOL call" $PTGX - $JNJ $VTYX LLY $PFE Citizens added, "On Wednesday, we hosted Dr. Marla Dubinsky, a gastroenterologist at Mt. Sinai and an IBD #KOL, for a discussion on the upcoming Phase 3 results for obefazimod in ulcerative colitis. Dr. Dubinsky is encouraged about the potential for positive results for obefazimod in moderate-to-severe ulcerative colitis due to the positive Phase 2b results, especially the clear improvement in endoscopy scores and benefit in highly refractory patients. $ABVX is one of our two high-conviction names into Phase 3 results that are coming soon."
0 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 14 at 11:56 PM
$GPCR is this a better oral GLP-1 investment than $PTGX & $VKTX ? $ALT is lonely in my biotech portfolio and wants an oral GLP-1 partner. 💊 Eating a cookie bomb for dessert - may need a GLP-1 soon 🤯
1 · Reply
Quantumup
Quantumup Jul. 14 at 11:36 AM
Citizens JMP reiterated $ABVX Mkt OP-$33 on its High-Conviction Catalysts Pick and said, "Phase 3 ABTECT results for obefazimod in moderate-to-severe UC patients anticipated near term" $PTGX - $JNJ $MRK LLY TAK $VTYX Citizens added. "We reiterate our Market Outperform rating and risk-adjusted, DCF derived $33 price target on Abivax. Abivax remains on track to report top-line results in 3Q25 from the Phase 3 induction trials evaluating obefazimod in moderate-to-severe ulcerative colitis. We remain confident in the potential for positive results in the Phase 3 trial driven by strong efficacy and safety/tolerability demonstrated the Phase 2b trial and the optimized Phase 3 trial design. This is one of two high-conviction clinical catalysts in our coverage in 3Q25."
0 · Reply
CH_Expat
CH_Expat Jul. 8 at 3:45 PM
$PTGX @Pika_Capital I sold in low 20s. This is why you are the better investor.
0 · Reply
Quantumup
Quantumup Jul. 2 at 6:56 PM
Piper Sandler reit'd $ABVX Overweight-$42 and said, "Remain OW rated on $ABVX shares heading into pivotal induction data for obefazimod in ulcerative colitis later this quarter." $PTGX - $JNJ RXDX - $MRK MORF - $LLY TAK VTYX Piper Sandler additionally said, "While we have long viewed obefazimod's profile in UC as differentiated based on its body of P2 data, we have fielded a number of investor questions around expectations for induction data and the bar for success. Herein, we provide a refresher of obefazimod's experience in UC to date, comparative safety/efficacy to approved advanced therapies, and our thoughts on the efficacy bar while addressing points of contention around this name. We also provide fresh survey feedback from our partners at Spherix, which points to continued enthusiasm around obefazimod's novel, oral MoA, clean safety profile, and potential for combo use. Bottom line, we see an attractive risk/reward on shares heading into data later this quarter, and remain buyers."
0 · Reply
StockHunter75
StockHunter75 Jul. 1 at 7:59 PM
$PTGX great time to buy the dip, adding some.
0 · Reply
agamemnus
agamemnus Jul. 1 at 3:07 PM
0 · Reply
Latest News on PTGX
Protagonist Therapeutics Reports Granting of Inducement Award

Apr 16, 2025, 4:05 PM EDT - 3 months ago

Protagonist Therapeutics Reports Granting of Inducement Award


Overlooked Stock: PTGX

Mar 10, 2025, 4:57 PM EDT - 4 months ago

Overlooked Stock: PTGX


Why Is Protagonist Therapeutics Stock Trading Higher On Monday?

Mar 10, 2025, 10:04 AM EDT - 4 months ago

Why Is Protagonist Therapeutics Stock Trading Higher On Monday?


Protagonist Therapeutics Reports Granting of Inducement Awards

Jan 6, 2025, 4:05 PM EST - 7 months ago

Protagonist Therapeutics Reports Granting of Inducement Awards


Protagonist Receives $34 Million from Warrant Exercises

Aug 9, 2023, 7:00 AM EDT - 2 years ago

Protagonist Receives $34 Million from Warrant Exercises


Quantumup
Quantumup Jul. 23 at 6:25 PM
H.C. Wainwright reit'd $ORKA Buy/$45 after Oruka📰that the FDA had cleared its IND application for its Phase 2a trial of ORKA-001 (the company's long-acting anti-IL-23p19 antibody) in moderate-to-severe PsO, called EVERLAST-A. $ABBV $PTGX - $JNJ #EDAV25 H.C. Wainwright said in its note: "This program is a randomized, double-blind, placebo-controlled Phase 2a trial designed to evaluate the safety and efficacy of a single dose level of ORKA-001 in moderate-to-severe psoriasis patients. EVERLAST-A will enroll approximately 80 patients, randomized 3:1 to receive ORKA-001 or matching placebo. The primary endpoint is PASI 100 at Week 16. ORKA-001 exposures are expected to match or exceed exposures in the KNOCKOUT study, providing a definitive test of whether higher exposures of an anti-IL-23p19 antibody can lead to greater efficacy. H.C. Wainwright went on to say:
0 · Reply
Quantumup
Quantumup Jul. 23 at 12:07 PM
Citizens⬆️ $ABVX to $95, reit Mkt-OP &said, "Stellar Phase 3 results for obefazimod in ulcerative colitis support potential for broad and early use in clinical practice" $ABBV $BMY PFE TAK $JNJ $PTGX VYTX LLY Guggenheim⬆️ $ABVX $101, reit Buy &said data clearly beat its/Buyside's exps.—believes obe S/B valued $7-10B range, given the recent M&A comps—Gugg's KOL called data "striking" Citizens said, "we reiterate our Market Outperform rating and increase our risk-adjusted, DCF-derived price target to $95 from $33 on Abivax SA. Yesterday afternoon, Abivax announced positive results from the two Phase 3 induction trials for obefazimod in moderate-to-severe ulcerative colitis. We view the results as highly compelling, with a pooled, placebo-adjusted clinical remission rate of 16.4% (p<0.0001) and a clean safety/tolerability profile. We raise our probability of approval and sales projections for the candidate, driving our increased price target." Guggenheim in its note said:
0 · Reply
Quantumup
Quantumup Jul. 21 at 1:15 PM
Stifel reiterated $ORKA Buy-$47 after $ORKA's disclosure of the IND clearance for ORKA-001 and then catching up w/ mgmt.. $ABBV $PTGX $JNJ #EADV25 UCBJY $MLTX Stifel said in its note: "We caught up with management who noted that the IND clearance was based on interim Ph1 data (safety/tolerability) and Ph2a sites are open and actively enrolling -- Ph1 results to be presented at #EADV in September. Recall, ORKA-001 is a next-gen IL-23p19 which is designed to explore greater exposure and improved dosing vs. mega-blockbuster Skyrizi based on exploratory IST results in Psoriasis demonstrating superior efficacy/potential for remission in patients dosed with 4x the normal psoriasis dose (LINK). Meanwhile, $ORKA is on track to release Ph1 data for ORKA-002 (next-gen IL-17A/F mAb) by YE25 following a continued strong launch for Bimzelx and upcoming Ph3 data for $MLTX's sonelokimab -- there is currently limited investor focus on $ORKA as a player in the IL-17A/F space."
0 · Reply
Quantumup
Quantumup Jul. 18 at 11:07 AM
Citizens reiterated $ABVX at a Market Outperform rating, a $33 PT and a High-Conviction name after its confidence in the pot'l for +VE obefazimod Ph3 results in moderate-to-severe ulcerative colitis were reinforced by its #KOL call" $PTGX - $JNJ $VTYX LLY $PFE Citizens added, "On Wednesday, we hosted Dr. Marla Dubinsky, a gastroenterologist at Mt. Sinai and an IBD #KOL, for a discussion on the upcoming Phase 3 results for obefazimod in ulcerative colitis. Dr. Dubinsky is encouraged about the potential for positive results for obefazimod in moderate-to-severe ulcerative colitis due to the positive Phase 2b results, especially the clear improvement in endoscopy scores and benefit in highly refractory patients. $ABVX is one of our two high-conviction names into Phase 3 results that are coming soon."
0 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 14 at 11:56 PM
$GPCR is this a better oral GLP-1 investment than $PTGX & $VKTX ? $ALT is lonely in my biotech portfolio and wants an oral GLP-1 partner. 💊 Eating a cookie bomb for dessert - may need a GLP-1 soon 🤯
1 · Reply
Quantumup
Quantumup Jul. 14 at 11:36 AM
Citizens JMP reiterated $ABVX Mkt OP-$33 on its High-Conviction Catalysts Pick and said, "Phase 3 ABTECT results for obefazimod in moderate-to-severe UC patients anticipated near term" $PTGX - $JNJ $MRK LLY TAK $VTYX Citizens added. "We reiterate our Market Outperform rating and risk-adjusted, DCF derived $33 price target on Abivax. Abivax remains on track to report top-line results in 3Q25 from the Phase 3 induction trials evaluating obefazimod in moderate-to-severe ulcerative colitis. We remain confident in the potential for positive results in the Phase 3 trial driven by strong efficacy and safety/tolerability demonstrated the Phase 2b trial and the optimized Phase 3 trial design. This is one of two high-conviction clinical catalysts in our coverage in 3Q25."
0 · Reply
CH_Expat
CH_Expat Jul. 8 at 3:45 PM
$PTGX @Pika_Capital I sold in low 20s. This is why you are the better investor.
0 · Reply
Quantumup
Quantumup Jul. 2 at 6:56 PM
Piper Sandler reit'd $ABVX Overweight-$42 and said, "Remain OW rated on $ABVX shares heading into pivotal induction data for obefazimod in ulcerative colitis later this quarter." $PTGX - $JNJ RXDX - $MRK MORF - $LLY TAK VTYX Piper Sandler additionally said, "While we have long viewed obefazimod's profile in UC as differentiated based on its body of P2 data, we have fielded a number of investor questions around expectations for induction data and the bar for success. Herein, we provide a refresher of obefazimod's experience in UC to date, comparative safety/efficacy to approved advanced therapies, and our thoughts on the efficacy bar while addressing points of contention around this name. We also provide fresh survey feedback from our partners at Spherix, which points to continued enthusiasm around obefazimod's novel, oral MoA, clean safety profile, and potential for combo use. Bottom line, we see an attractive risk/reward on shares heading into data later this quarter, and remain buyers."
0 · Reply
StockHunter75
StockHunter75 Jul. 1 at 7:59 PM
$PTGX great time to buy the dip, adding some.
0 · Reply
agamemnus
agamemnus Jul. 1 at 3:07 PM
0 · Reply
vu_jade
vu_jade Jul. 1 at 3:50 AM
$PTGX decent chart
0 · Reply
judgeyoung2
judgeyoung2 Jun. 30 at 8:37 PM
$PTGX they are pursuing both oral and subcutaneous versions of the drug
0 · Reply
CrispDry
CrispDry Jun. 30 at 5:05 PM
$PTGX praying for a win AH
1 · Reply
StockConsultant
StockConsultant Jun. 30 at 1:45 PM
$PTGX Protagonist Therapeutics stock, nice open and top of range breakout at https://stockconsultant.com/?PTGX
0 · Reply
AnomalyDetective
AnomalyDetective Jun. 29 at 12:06 PM
Sharing a few forensic value selections from the Negative / Positive forensic mid-year portfolios: $NKTR $BTDR $PTGX $SIGA Exclusively based on four fundamental financial algorithms used in forensic accounting to see if stocks at extremes can outperform. https://seekingalpha.com/article/4798073-top-forensic-value-mid-year-2025-selections-highest-positive-negative-scoring-stocks-july
0 · Reply
CrispDry
CrispDry Jun. 27 at 9:03 PM
$AKRO multi million share trades AH on each. Is this normal? $PTGX $XBI
0 · Reply
CrispDry
CrispDry Jun. 27 at 8:00 PM
$PTGX big buys at close
0 · Reply
judgeyoung2
judgeyoung2 Jun. 26 at 11:41 PM
$PTGX obesity drug where you at
1 · Reply
mikesterz7
mikesterz7 Jun. 26 at 12:38 AM
$PTGX Future $100 stock
0 · Reply
CrispDry
CrispDry Jun. 26 at 12:11 AM
$ALT still waiting on $PTGX obesity data. Any day now. More likely that $JNJ will buy them up instead of altimunne or Viking
1 · Reply
CrispDry
CrispDry Jun. 25 at 3:32 PM
$PTGX where’s the obesity data?
2 · Reply
CrispDry
CrispDry Jun. 24 at 10:31 PM
$JNJ updating my post - I wrote wrong month: $JNJ someone still has 10,000 $160 calls for July open here. Either they are releasing data or making a splash that is expected to boost the share price $VKTX $PTGX
0 · Reply